Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857663 | 0.85 | ALDH1A1 (0.49) | ALDH1A1MAPTKDM4EMEN1GAA | |
| SCHEMBL16505741 | 0.84 | ALDH1A1 (0.36) | ALDH1A1MAPTKDM4EMEN1GAA | |
| SCHEMBL15416184 | 0.84 | MAPT (0.43) | ALDH1A1MAPTKDM4EMEN1GAA | |
| SCHEMBL1700776 | 0.83 | ALDH1A1 (0.41) | ALDH1A1MAPTKDM4EMEN1GAA | |
| SCHEMBL855428 | 0.81 | PSEN1 (0.43) | ALDH1A1MAPTKDM4EGAAKMT2A | |
| SCHEMBL5111017 | 0.81 | TLR4 (0.43) | ALDH1A1MAPTKDM4EMEN1GAA | |
| SCHEMBL25981634 | 0.81 | ALDH1A1 (0.40) | ALDH1A1MAPTKDM4EMEN1GAA | |
| SCHEMBL7663667 | 0.81 | ALDH1A1 (0.40) | ALDH1A1MAPTKDM4EMEN1GAA | |
| SCHEMBL15684078 | 0.80 | ALDH1A1 (0.45) | ALDH1A1MAPTKDM4EMEN1GAA | |
| SCHEMBL14731543 | 0.80 | TLR4 (0.39) | ALDH1A1MAPTKDM4EMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117229208-B | Condensed ring compound, preparation method and medical application thereof | 上海泽德曼医药科技有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117229208-A | Condensed ring compound, preparation method and medical application thereof | 上海泽德曼医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| EP-2210890-A1 | Oxadiazole derivatives as S1P1 receptor agonists | Almirall, S.A. (ES) | 2010-07-28 | — | — | EP | disclosed |
| EP-2210890-A1 | Oxadiazole derivatives as S1P1 receptor agonists | Almirall, S.A. (ES) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010081692-A1 | OXADIAZOLE DERIVATIVES AS SLPL RECEPTOR AGONISTS | ALMIRALL, S.A. (ES) | 2010-07-22 | — | — | WO | disclosed |
| CN-100432049-C | Cycloalkene derivatives, process for producing the same and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2008-11-12 | — | — | CN | disclosed |
| EP-1524263-A1 | prodrugs containing cycloalkene derivatives | Takeda Pharmaceutical Company Limited (JP) | 2005-04-20 | — | — | EP | disclosed |
| EP-1063228-B1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICAL (JP) | 2005-01-19 | — | — | EP | disclosed |
| US-6495604-B1 | SUCH AS D-ETHYL-6-(N-(2,4-DIFLUOROPHENYL)SULFAMOYL)-1-CYCLOHEXENE-1-CARBOXYLATE FOR INHIBITING NITRIC OXIDE AND/OR CYTOKINE PRODUCTION; FOR PREVENTING OR TREATING CARDIAC DISEASE, AUTOIMMUNE DISEASE OR SEPTIC SHOCK | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| CN-1291184-A | Cycloalkene derivatives, process for producing the same and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-04-11 | — | — | CN | disclosed |
| EP-1063228-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | S1PR1, S1PR3, S1PR2 | ALDH1A1 2114/4885MAPT 4226/4885KDM4E 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.